doxorubicin accord 2 mg/ml koncentrat till infusionsvätska, lösning
accord healthcare b.v. - doxorubicinhydroklorid - koncentrat till infusionsvätska, lösning - 2 mg/ml - doxorubicinhydroklorid 2 mg aktiv substans - doxorubicin
doxorubicin sanoswiss 2 mg/ml koncentrat till infusionsvätska, lösning
sanoswiss uab - doxorubicinhydroklorid - koncentrat till infusionsvätska, lösning - 2 mg/ml - doxorubicinhydroklorid 2 mg aktiv substans - doxorubicin
doxorubicin mylan 2 mg/ml koncentrat till infusionsvätska, lösning
mylan hospital as - doxorubicinhydroklorid - koncentrat till infusionsvätska, lösning - 2 mg/ml - doxorubicinhydroklorid 2 mg aktiv substans - doxorubicin
doxorubicin teva 2 mg/ml injektionsvätska, lösning
teva sweden ab - doxorubicinhydroklorid - injektionsvätska, lösning - 2 mg/ml - doxorubicinhydroklorid 2 mg aktiv substans - doxorubicin
doxorubicin ebewe 2 mg/ml injektionsvätska, lösning
ebewe pharma ges.m.b.h.nfg.kg - doxorubicinhydroklorid - injektionsvätska, lösning - 2 mg/ml - doxorubicinhydroklorid 2 mg aktiv substans - doxorubicin
doxorubicin stada 2 mg/ml injektionsvätska, lösning
stada arzneimittel ag - doxorubicinhydroklorid - injektionsvätska, lösning - 2 mg/ml - doxorubicinhydroklorid 2 mg aktiv substans - doxorubicin
doxorubicin copharma 2 mg/ml koncentrat till infusionsvätska, lösning
copharma aps - doxorubicinhydroklorid - koncentrat till infusionsvätska, lösning - 2 mg/ml - doxorubicinhydroklorid 2 mg aktiv substans - doxorubicin
doxorubicin teva 2 mg/ml pulver till koncentrat till infusionsvätska, lösning
teva pharma bv - doxorubicinhydroklorid - pulver till koncentrat till infusionsvätska, lösning - 2 mg/ml - doxorubicinhydroklorid 2 mg aktiv substans; laktos (vattenfri) hjälpämne - doxorubicin
doxorubicin mylan 2 mg/ml pulver till koncentrat till infusionsvätska, lösning
mylan hospital as - doxorubicinhydroklorid - pulver till koncentrat till infusionsvätska, lösning - 2 mg/ml - doxorubicinhydroklorid 2 mg aktiv substans; laktosmonohydrat hjälpämne - doxorubicin
zolsketil pegylated liposomal
accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.